Frangoul et al. [128] also reported that two patients, one with transfusion-deficient beta-thalassaemia (TDT) and one with sickle cell disease were administered with a Cas9 to target the BCL11A transcription factor. The gene discussed is BCL11A; the disease is beta thalassemia.